Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease-Reference-Cited by-同舟云学术

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

Published:2008-01 Issue:1 Volume:29 Page:161-168
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Levandis Giovanna,Bazzini Eleonora,Armentero Marie-Thérèse,Nappi Giuseppe,Blandini Fabio

Publisher

Elsevier BV

Subject

Neurology

Reference63 articles.

1. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP;Aguirre;Brain Res.,2005

2. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems;Alagarsamy;Nat. Neurosci.,1999

3. NMDA-induced phosphorylation and regulation of mGluR5;Alagarsamy;Pharmacol. Biochem. Behav.,2002

4. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease;Andersson;Neurobiol. Dis.,1999

5. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment;Andersson;Eur. J. Neurosci.,2003

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain;Journal of Chemical Neuroanatomy;2024-07

2. Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease;Central Nervous System Agents in Medicinal Chemistry;2024-04

3. Metabotropic glutamate receptors in Parkinson's disease;International Review of Neurobiology;2023

4. Levodopa therapy for Parkinson's disease;Galenika Medical Journal;2023

5. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic;Neurodegenerative Disease Management;2022-08